Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Impel Pharmaceuticals Inc. - Common Stock (NQ: IMPL )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Impel Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
From Impel Pharmaceuticals
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Impel Pharmaceuticals: Q1 Earnings Insights
Impel Pharmaceuticals (NASDAQ:IMPL) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 34 companies set new 52-week lows. 
Via Benzinga
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
From Impel Pharmaceuticals
Via GlobeNewswire
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
From Impel Pharmaceuticals
Via GlobeNewswire
Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
From Impel Pharmaceuticals
Via GlobeNewswire
Impel NeuroPharma's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, Impel NeuroPharma's (NASDAQ:IMPL) reported sales totaled $2.80 million. Despite a 6.55% increase in earnings, the company posted a loss of $25.20... 
Via Benzinga
Impel Pharmaceuticals: Q2 Earnings Insights
  Impel Pharmaceuticals (NASDAQ:IMPL) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Outlook For Impel NeuroPharma
  Impel NeuroPharma (NASDAQ:IMPL) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement. 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Impel Commences Mid-Stage Autism Spectrum Disorder Study
Impel Pharmaceuticals (NASDAQ: IMPL) has dosed the first patient in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic. 
Via Benzinga
Impel NeuroPharma's Return On Capital Employed Insights
Impel NeuroPharma (NASDAQ:IMPL) brought in sales totaling $1.76 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.0%, resulting in a loss of $26.97 million. 
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
Mizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target
Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal... 
Via Benzinga
Impel NeuroPharma Earnings Preview
Impel NeuroPharma (NASDAQ:IMPL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Impel... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding... 
Via Benzinga
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to... 
Via Benzinga
Benzinga's After-Hours Movers & News: Williams-Sonoma, PagerDuty And More
Benzinga’s “After-Hours Movers & News” highlights the biggest movers of the day. The information on the price action is collected using Benzinga Pro's... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Impel Neuro's Trudhesa Nasal Spray Migraine Treatment Performed Better Than Expected In Q4
Impel NeuroPharma Inc (NASDAQ: IMPL) stated that since the October 2021 commercial launch, the performance of Trudhesa has exceeded expectations with over 4,200... 
Via Benzinga
41 Stocks Moving In Monday's Mid-Day Session
Gainers Casper Sleep Inc. (NYSE: CSPR) shares climbed 87.1% to $6.64 after the company agreed to be acquired by Durational Capital Management. The company also reported Q3... 
Via Benzinga
Earnings Scheduled For November 15, 2021
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 35.02% to $7.22 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.